C
KROS icon

Chescapmanager’s Keros Therapeutics KROS Stock Holding History

Chescapmanager’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,105
Closed -$402K – 45
2023
Q4 		$402K Hold
10,105
– – 0.04% 39
2023
Q3 		$322K Hold
10,105
– – 0.04% 39
2023
Q2 		$406K Hold
10,105
– – 0.06% 38
2023
Q1 		$431K Hold
10,105
– – 0.07% 41
2022
Q4 		$485K Hold
10,105
– – 0.11% 35
2022
Q3 		$380K Hold
10,105
– – 0.09% 39
2022
Q2 		$279K Hold
10,105
– – 0.07% 39
2022
Q1 		$550K Hold
10,105
– – 0.07% 44
2021
Q4 		$591K Hold
10,105
– – 0.08% 54
2021
Q3 		$400K Hold
10,105
– – 0.06% 54
2021
Q2 		$429K Buy
+10,105
New +$547K 0.05% 60

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Chescapmanager's KROS Position: Q1 2024 in Review

Chescapmanager sold out of Keros Therapeutics (KROS) in Q1 2024, closing a stake of 10,105 shares — an estimated $402K sold.

Chescapmanager first reported a position in KROS in Q2 2021 and held it in 11 quarters. The position peaked at $591K in Q4 2021. 147 funds tracked by Wall St. Rank hold KROS as of Q1 2024.

  • Chescapmanager reported no remaining Keros Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Chescapmanager sold 10,105 Keros Therapeutics shares in Q1 2024, an estimated $402K.
  • Chescapmanager first reported a position in Keros Therapeutics in Q2 2021 and held it in 11 quarters.
  • Chescapmanager's Keros Therapeutics position peaked at $591K in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2024.

Based on Chescapmanager's 13F filing for Q1 2024, filed 15 May 2024.